




Correction to: Setomimycin as a potential molecule for COVID-19 target: in silico approach and in vitro validation

Ravi S. Manhas^{1,5} · Harshita Tiwari^{2,5} · Mateen Noor^{3,5} · Ajaz Ahmed^{2,5} · Jyoti Vishwakarma^{4,5} · Raja B. M. Tripathi^{4,5} · Ravishankar Ramachandran^{4,5} · Sreedhar Madishetti^{3,5} · Debaraj Mukherjee^{2,5} · Amit Nargotra^{2,5} · Asha Chaubey^{1,5} 

Published online: 29 August 2022

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Correction to: *Molecular Diversity*

<https://doi.org/10.1007/s11030-022-10441-5>

In the original publication, the order of authors was published incorrectly. The correct version is given in this correction.

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s11030-022-10441-5>.

✉ Asha Chaubey
achaubey@iiim.res.in

✉ Amit Nargotra
anargotra@iiim.res.in

- ¹ Fermentation & Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
- ² Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
- ³ Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
- ⁴ Division of Biochemistry and Structural Biology, CSIR- Central Drug Research Institute, Lucknow 226031, India
- ⁵ Academy of Scientific and Innovative Research, CSIR- Human Resource Development Centre, Campus Ghaziabad, Ghaziabad 201002, India